
## Maria T Desancho

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2030933/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis. Blood Advances, 2022, 6, 664-671.	2.5	53
2	Delayed diagnosis of congenital thrombotic thrombocytopenic purpura in a patient with recurrent strokes. Journal of Thrombosis and Thrombolysis, 2022, 53, 734-738.	1.0	2
3	Diagnosis and management of severe congenital protein C deficiency (SCPCD): Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2022, 20, 1735-1743.	1.9	8
4	Management and outcomes of mild hemophiliacs and hemophilia carriers during pregnancy and peripartum period: a hemophilia treatment center experience in the United States. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 9759-9764.	0.7	1
5	Major hemorrhage and mortality in COVID-19 patients on therapeutic anticoagulation for venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2022, 54, 431-437.	1.0	4
6	Prediction and Prevention of Cancer-Associated Thromboembolism. Oncologist, 2021, 26, e2-e7.	1.9	33
7	American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Advances, 2021, 5, 872-888.	2.5	310
8	Mechanisms of Ischemic Stroke in Patients with Cancer: A Prospective Study. Annals of Neurology, 2021, 90, 159-169.	2.8	31
9	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. Blood Advances, 2021, 5, 3951-3959.	2.5	49
10	Management and Outcomes of Women with Antiphospholipid Antibodies or Antiphospholipid Syndrome during Pregnancy. Blood, 2021, 138, 1018-1018.	0.6	0
11	Impairment of Annexin A2-Mediated Cell Surface Fibrinolysis in Nonalcoholic Steatohepatitis Cirrhosis with Portal Vein Thrombosis. Blood, 2021, 138, 1030-1030.	0.6	0
12	D-dimer cut-off points and risk of venous thromboembolism in adult hospitalized patients with COVID-19. Thrombosis Research, 2020, 196, 318-321.	0.8	45
13	<p>Understanding Sideroblastic Anemia: An Overview of Genetics, Epidemiology, Pathophysiology and Current Therapeutic Options</p> . Journal of Blood Medicine, 2020, Volume 11, 305-318.	0.7	23
14	Successful outcome with eculizumab treatment in a patient with antiphospholipid syndrome presenting with an unusual thrombotic storm. Journal of Thrombosis and Thrombolysis, 2020, 52, 597-600.	1.0	8
15	Anticoagulant interventions in hospitalized patients with COVIDâ€19: A scoping review of randomized controlled trials and call for international collaboration. Journal of Thrombosis and Haemostasis, 2020, 18, 2958-2967.	1.9	98
16	Management of pregnancy in women with factor VII deficiency: A case series. Haemophilia, 2020, 26, 652-656.	1.0	16
17	Peri- and Postpartum Management of Patients With Factor XI Deficiency. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961988026.	0.7	8
18	Thrombotic risk factors in patients with antiphospholipid syndrome: a single center experience. Journal of Thrombosis and Thrombolysis, 2019, 48, 233-239.	1.0	10

MARIA T DESANCHO

#	Article	IF	CITATIONS
19	Enoxaparin vs Aspirin in Patients With Cancer and Ischemic Stroke. JAMA Neurology, 2018, 75, 379.	4.5	52
20	Delayed diagnosis of congenital sideroblastic anemia. Seminars in Hematology, 2018, 55, 177-178.	1.8	1
21	Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. Blood Advances, 2017, 1, 2320-2324.	2.5	40
22	Abstract TP72: Pilot Trial of Enoxaparin versus Aspirin in Cancer Patients with Stroke: the TEACH Study. Stroke, 2017, 48, .	1.0	0
23	Inherited antithrombin deficiency and anabolic steroids. Blood Coagulation and Fibrinolysis, 2016, 27, 717-719.	0.5	6
24	Clinical adherence to thrombophilia screening guidelines at a major tertiary care hospital. Journal of Thrombosis and Haemostasis, 2016, 14, 982-986.	1.9	15
25	Clinical presentations, risk factors, treatment and outcomes in patients with splanchnic vein thrombosis: a single-center experience. Journal of Thrombosis and Thrombolysis, 2016, 42, 267-271.	1.0	6
26	Dalteparin was at least as effective as UFH for VTE prevention in critically ill patients, with similar costs. Annals of Internal Medicine, 2015, 162, JC13.	2.0	1
27	ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia - study protocol for a randomized controlled trial. Trials, 2015, 16, 208.	0.7	46
28	Adherence to guidelines for perioperative management of anticoagulation results in decreased bleeding complications. Blood Coagulation and Fibrinolysis, 2015, 26, 426-429.	0.5	4
29	Life-threatening bleeding in a patient with mild hemophilia A and heterozygosity for von Willebrand disease Type 2N. International Journal of Hematology, 2014, 100, 602-606.	0.7	1
30	Risk of venous thrombosis varies with different types of combined oral contraceptives. Evidence-Based Medicine, 2014, 19, e11-e11.	0.6	1
31	Role of Novel Anticoagulants for Patients with Mechanical Heart Valves. Current Atherosclerosis Reports, 2014, 16, 448.	2.0	6
32	The effects of Eculizumab on the pathology of malignant atrophic papulosis. Orphanet Journal of Rare Diseases, 2013, 8, 185.	1.2	48
33	Lingual thrombosis in a woman with antiphospholipid syndrome. American Journal of Obstetrics and Gynecology, 2013, 208, e3-e4.	0.7	13
34	Prophylactic dose fondaparinux for 6â€weeks in superficial thrombophlebitis of the legs reduces the risk for symptomatic thromboembolic complications. Evidence-Based Medicine, 2013, 18, 28-29.	0.6	0
35	A patient with â€~spontaneous' heparin-induced thrombocytopenia and thrombosis after undergoing knee replacement. Blood Coagulation and Fibrinolysis, 2011, 22, 73-75.	0.5	25
36	Risk factors for clinical manifestations in carriers of Factor V Leiden and prothrombin gene mutations. Blood Coagulation and Fibrinolysis, 2010, 21, 11-15.	0.5	8

MARIA T DESANCHO

#	Article	IF	CITATIONS
37	Thrombophilia and the risk of thromboembolic events in women on oral contraceptives and hormone replacement therapy. Blood Coagulation and Fibrinolysis, 2010, 21, 534-538.	0.5	13
38	Hematological Issues in Critically III Patients with Cancer. Critical Care Clinics, 2010, 26, 107-132.	1.0	18
39	Prophylactic dosing adjustment in pregnancy based upon measurements of anti-factor Xa levels. Journal of Maternal-Fetal and Neonatal Medicine, 2005, 18, 329-331.	0.7	17
40	ls measurement of antifactor Xa necessary in the pregnant anticoagulated patient?. American Journal of Obstetrics and Gynecology, 2003, 189, S147.	0.7	0
41	BLEEDING AND THROMBOTIC COMPLICATIONS IN CRITICALLY ILL PATIENTS WITH CANCER. Critical Care Clinics, 2001, 17, 599-622.	1.0	25